Spiolto Respimat

Per actuation Tiotropium 2.5 mcg, olodaterol 2.5 mcg

Maintenance bronchodilator treatment for symptomatic relief in adult patients w/ COPD.

2 puffs once daily.

Hypersensitivity to tiotropium, olodaterol & atropine or its derivatives eg, ipratropium or oxitropium.

Hypersensitivity. Not to be used in asthma, acute episodes of bronchospasm ie, rescue therapy. Discontinue use if paradoxical bronchospasm occurs. Narrow-angle glaucoma, prostatic hyperplasia or bladder neck obstruction. CV disorders eg, history of MI, unstable or life-threatening arrhythmia, hospitalization due to heart failure, paroxysmal tachycardia; ischaemic heart disease, severe cardiac decompensation, hypertrophic obstructive cardiomyopathy, HTN, aneursym; convulsive disorders or thyrotoxicosis, known or suspected QT interval prolongation & patients unusually responsive to sympathomimetic amines. Hypokalemia, hyperglycemia. Dry mouth. Avoid contact w/ eyes. Not to be used in conjunction w/ medications containing long-acting β₂-adrenergic agonists, halogenated hydrocarbon anaesth. May affect ability to drive & use machines. Moderate to severe renal impairment (CrCl <50 mL/min). Severe hepatic impairment. Pregnancy & lactation. Childn <18 yr.

Dry mouth.

Not recommended w/ anticholinergic agents. Potentiated undesirable effects w/ other adrenergic agents. Potentiated hypokalemic effect w/ xanthine derivatives, steroids or non-K sparing diuretics. Weakened or antagonized effect by β-blockers. Potentiated CV action w/ MAOIs, TCAs, other drugs known to prolong QTc interval. Increased systemic exposure w/ ketoconazole.

Antiasthmatic & COPD Preparations

R03AL06 - olodaterol and tiotropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.

C